LXRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lexicon Pharmaceuticals Inc (LXRX) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has bullish moving averages and a positive analyst outlook, the company's financial performance is weak, with significant YoY declines in revenue, net income, and EPS. Additionally, there are no recent news catalysts or strong trading signals to support immediate investment.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), but the MACD is below 0 and negatively expanding, indicating bearish momentum. RSI is neutral at 32.889. Key support is at 1.697, and resistance is at 1.804. The stock has a 70% chance of a slight decline (-0.42%) in the next day and a modest increase (1.45%) in the next week.
Analysts have raised price targets recently, with Citi increasing its target to $2.30 and H.C. Wainwright raising it to $6, citing progress in clinical trials and potential partnerships.
The company's financials for Q4 2025 show a significant decline in revenue (-79.31% YoY), net income (-54.01% YoY), and EPS (-55.56% YoY). There are no recent news catalysts or significant hedge fund or insider trading activity.
In Q4 2025, revenue dropped to $5.49M (-79.31% YoY), net income dropped to -$15.53M (-54.01% YoY), and EPS dropped to -$0.04 (-55.56% YoY). Gross margin also declined slightly to 96.34% (-2.38% YoY).
Analysts maintain a Buy rating with increased price targets. Citi raised its target to $2.30, and H.C. Wainwright raised it to $6, citing progress in clinical trials and potential partnerships.
